Bjørn
From Norway to China for BCMA CAR-T cell therapy: how Bjørn navigated a month of COVID isolation and reached complete remission from multiple myeloma.
Why the Family Contacted CancerFax
Bjørn's family were facing two problems at once: a complex cancer and a world in lockdown. They needed clear answers about where this kind of therapy was offered, whether Bjørn could be considered for it, and how an international patient could realistically travel into China during the pandemic. These were not questions they could answer on their own.
Cell therapy for multiple myeloma is available at only a few experienced centres. Finding the right one took specialist knowledge.
Eligibility for CAR-T depends on the disease, prior treatment, and overall health. Understanding the requirements needed expert review.
Entry rules, quarantine, and hospital admission during the pandemic required careful, step by step coordination.
"We did not know if it was even possible to get him there. We only knew we had to try, and we needed someone who could help us find the way."— Bjørn's family
How CancerFax Helped
CancerFax worked with Bjørn's family to organise his medical records, identify a suitable specialist centre, and manage the practical side of travelling for treatment during the pandemic. The aim was to give the family a clear path and to handle the coordination so they could focus on Bjørn.
Bjørn's blood results, myeloma history, and treatment records were compiled and prepared so the hospital team could review his case quickly.
CancerFax identified Lu Daopei Hospital in China as a centre with established experience in CAR-T cell therapy for blood cancers.
Medical documents were translated and communication between Bjørn's family and the hospital team was managed throughout.
CancerFax helped coordinate Bjørn's entry into China, his month of COVID isolation, and his transfer to the hospital for treatment.
Bjørn's Treatment Journey
Key steps from diagnosis to treatment and beyond.
Bjørn was diagnosed with IgG-lambda multiple myeloma in Norway, where he was monitored over time. Blood tests tracked his M-protein and free light chain levels.
Despite the care he received at home, Bjørn's blood results showed the myeloma was still active, with a rising M-protein. The family began looking at what other options might exist.
Bjørn's family contacted CancerFax to understand whether BCMA CAR-T cell therapy could be an option and where it might be accessed. CancerFax reviewed his records and identified Lu Daopei Hospital in China as a suitable centre.
With international travel heavily restricted by COVID-19, CancerFax helped coordinate Bjørn's journey into China and the entry requirements that applied at the time.
Before he could be admitted, Bjørn spent about a month in isolation at a hotel, in line with the COVID-19 rules for arriving patients. CancerFax stayed in contact with the family throughout this period.
Once cleared, Bjørn was admitted to Lu Daopei Hospital, where the haematology and cell therapy team completed his evaluation and delivered BCMA CAR-T cell therapy.
Following treatment, Bjørn's multiple myeloma went into complete remission. He continued under medical follow-up to monitor his response over time.
Every patient's treatment plan is individual. The pathway above describes this specific case — not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Bjørn Is Today
After his BCMA CAR-T cell therapy at Lu Daopei Hospital, Bjørn reached complete remission of his multiple myeloma. For a disease that is known to return, getting to this point was an important and hopeful result for him and his family.
Like all patients who receive CAR-T cell therapy, Bjørn continues under regular medical follow-up. Ongoing monitoring helps his care team watch his response and act early if anything changes. Multiple myeloma is managed over the long term, and follow-up remains part of his care.
“"After everything we went through to get there, hearing the word remission meant the world to us."”— Bjørn's family
What Other Families Can Learn
Bjørn's journey offers a few practical lessons for families weighing advanced options for myeloma or other blood cancers.
When myeloma keeps returning, a specialist review can reveal newer options, such as CAR-T, that may not be offered locally.
CAR-T cell therapy has specific medical requirements. Confirming whether a patient is a suitable candidate early saves time and avoids false hope.
During the pandemic, entry rules and isolation added weeks to the journey. Starting early made the difference between reaching treatment and missing the window.
Records, translation, travel, and a month of isolation are a lot to manage alone. Coordinated navigation made the process workable for Bjørn's family.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
© CancerFax · Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.